Bora CDMO Bora CDMO

X

Find Cenobamate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Cenobamate
Also known as: Xcopri, 913088-80-9, Cenobamate [inn], Ykp3089, Ykp-3089, P85x70rzws
Molecular Formula
C10H10ClN5O2
Molecular Weight
267.67  g/mol
InChI Key
GFHAXPJGXSQLPT-VIFPVBQESA-N
FDA UNII
P85X70RZWS

Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
1 2D Structure

Cenobamate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
2.1.2 InChI
InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
2.1.3 InChI Key
GFHAXPJGXSQLPT-VIFPVBQESA-N
2.1.4 Canonical SMILES
C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl
2.1.5 Isomeric SMILES
C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
2.2 Other Identifiers
2.2.1 UNII
P85X70RZWS
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Carbamate (ester), (alphar)-

2. Carbamic Acid (r)-(+)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Ester

3. Xcopri

4. Ykp-3089

5. Ykp3089

2.3.2 Depositor-Supplied Synonyms

1. Xcopri

2. 913088-80-9

3. Cenobamate [inn]

4. Ykp3089

5. Ykp-3089

6. P85x70rzws

7. [(1r)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate

8. Carbamic Acid (r)-(+)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Ester

9. Ontozry

10. Unii-p85x70rzws

11. Xcopri (tn)

12. Cenobamate [mi]

13. Ykp-3089 Cenobamate

14. Cenobamate (usan/inn)

15. Cenobamate [usan:inn]

16. Cenobamate [usan]

17. Cenobamate [who-dd]

18. Schembl1682643

19. Cenobamate [orange Book]

20. Chembl3989949

21. Gtpl10773

22. Ykp3089ykp3089

23. Dtxsid001027948

24. Ex-a3604

25. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, 2-carbamate, (alphar)-

26. Db06119

27. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Carbamate (ester), (alphar)-

28. Hy-17607

29. Cs-0014686

30. D11150

31. Q27286352

32. (1r)-1-(2-chlorophenyl)-2-(tetrazol-yl)ethyl)carbamate

33. (1r)-1-(2-chlorophenyl)-2-(2h-1,2,3,4-tetrazol-2-yl)ethyl Carbamate

34. (1r)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Carbamate

35. 2h-tetrazole-2-ethanol, .alpha.-(2-chlorophenyl)-, 2-carbamate, (.alpha.r)-

36. 2h-tetrazole-2-ethanol, .alpha.-(2-chlorophenyl)-, Carbamate (ester), (.alpha.r)-

37. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Yl)ethyl)carbamate Carbamate (ester), (.alpha.r)-

2.4 Create Date
2006-12-11
3 Chemical and Physical Properties
Molecular Weight 267.67 g/mol
Molecular Formula C10H10ClN5O2
XLogP31.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count5
Exact Mass267.0523023 g/mol
Monoisotopic Mass267.0523023 g/mol
Topological Polar Surface Area95.9 Ų
Heavy Atom Count18
Formal Charge0
Complexity293
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Cenobamate is indicated for the treatment of partial onset seizures in adults.


Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.


5 Pharmacology and Biochemistry
5.1 Pharmacology

The mechanism of cenobamate is unknown, however it modulates GABAA and inhibit voltage gated sodium channels. Cenobamate is given once daily and so it has a long duration of action. The therapeutic window is wide as doses of 750mg can be well tolerated. Patients should be counselled regarding the risk of DRESS syndrome, QT interval shortening, suicidal behavior, and neurological adverse effects.


5.2 MeSH Pharmacological Classification

Anticonvulsants

Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)


5.3 ATC Code

N03AX


N - Nervous system

N03 - Antiepileptics

N03A - Antiepileptics

N03AX - Other antiepileptics

N03AX25 - Cenobamate


5.4 Absorption, Distribution and Excretion

Absorption

Cenobamate is 88% orally bioavailable with a Tmax of 1-4 hours. A high fat meal does not significantly impact the pharmacokinetics of cenobamate.


Route of Elimination

Cenobamate is 87.8% eliminated in the urine and 5.2% in the feces.


Volume of Distribution

The apparent volume of distribution of cenobamate is 40-50L.


Clearance

The apparent oral clearance of cenobamate is 0.45-0.63L/h for a 100-400mg/day dose.


5.5 Metabolism/Metabolites

Data regarding the metabolism of cenobamate is lacking, however it is mostly glucuronidated by UGT2B7 and UGT2B4 or oxidized by a number of cytochromes.


5.6 Biological Half-Life

The terminal half life of cenobamate is 50-60h.


5.7 Mechanism of Action

Cenobamate inhibits voltage gated sodium channels and is a positive GABAA modulator. However, the exact mechanism of action remains unknown. Inhibition of voltage gated sodium channels increases the threshold for generating action potentials and decreases the number of action potentials.


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY